News

Lupus Nephritis Drug Candidate Voclosporin Granted FDA Fast Track Designation

Aurinia Pharmaceuticals recently announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to voclosporin, a next-generation calcineurin inhibitor under development to treat patients with lupus nephritis (LN) and other autoimmune diseases. LN is a kidney inflammation caused by systemic lupus erythematosus (SLE) in which patients may develop proteinuria,…

Lupus Patients May Benefit from Identification of RNAs that Regulate Antibodies in Mice

Researchers from Singapore’s leading science institute, A*STAR, found that a group of small noncoding RNAs, called mir-17-92, regulate B-cell function and antibodies in mice. The results may help pave the way for new lupus treatments and other diseases linked to B-cell dysfunction. Antibody-producing B-cells are a crucial part of our defense against pathogens. In autoimmune…